Outbreak by KPC-62-producing ST307 Klebsiella pneumoniae isolates resistant to ceftazidime/avibactam and cefiderocol in a university hospital in Madrid, Spain [PDF]
, 2023 8 p.Objectives: Ceftazidime/avibactam and cefiderocol are two of the latest antibiotics with activity against a wide variety of Gram-negatives, including carbapenem-resistant Enterobacterales.
Pablo Sánchez, Raúl De
core +1 more source
Evolution of β-lactamase-mediated cefiderocol resistance [PDF]
, 2022 Background: Cefiderocol is a novel siderophore β-lactam with improved hydrolytic stability toward β-lactamases, including carbapenemases, achieved by combining structural moieties of two clinically efficient cephalosporins, ceftazidime and cefepime ...
Frøhlich, Christopher +4 more
core +1 more source
Journal of Global Antimicrobial Resistance, 2021 : Objectives: The prevalence of Gram-negative bacteria (GNB) demonstrating extensive, multiple antimicrobial resistance is increasing in England, leaving few treatment choices.
Vanya Gant +4 more
doaj +1 more source
Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients
Pharmaceutics, 2022 Background: Cefiderocol is a siderophore cephalosporin antibiotic active against Gram-negative bacteria, including extended-spectrum beta-lactamase and carbapenemase-producing strains.
Noël Zahr +11 more
doaj +1 more source
Microbiology Spectrum, 2022 Cefiderocol has been approved in the United States and Europe but not in China. We aim to evaluate carbapenem-resistant Enterobacterales (CRE) susceptibility to cefiderocol to provide baseline data and investigate the resistance mechanism.
Qi Wang +16 more
doaj +1 more source
In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany
Journal of Global Antimicrobial Resistance, 2022 : Objectives: Widespread antimicrobial resistance in Gram-negative bacteria (GNB), particularly carbapenem resistance, represents a major clinical challenge.
Philipp Thelen +5 more
doaj +1 more source
Real-World Experience With Cefiderocol Therapy for Pseudomonas aeruginosa and Other Multidrug Resistant Gram-Negative Infections Within the Veterans Health Administration, 2019–2022 [PDF]
, 2023 OBJECTIVE: Single-center and regional studies have reported outcomes after treatment with cefiderocol, a novel siderophore cephalosporin. We report on real-world use, clinical outcomes, and microbiological outcomes with cefiderocol therapy within the ...
Amenta, Eva +3 more
core +2 more sources
Therapeutic Advances in Urology, 2022 Cefiderocol is a unique siderophore cephalosporin antimicrobial agent that has shown promise in treating complicated urinary tract infections (cUTI). Urinary tract infections are commonly diagnosed infections with risk increasing with age and prevalence ...
Hongmei Wang, Brittany N. Palasik
doaj +1 more source
Navigating the Challenges of <i>Stenotrophomonas maltophilia</i> Infections in Chronic Kidney Disease: A Case Report. [PDF]
Clin Case RepABSTRACT S. maltophilia is a multidrug‐resistant nosocomial pathogen that poses significant challenges in CKD patients. Antibiotic selection in CKD is complicated by nephrotoxicity concerns and limited clinical data. Combination therapy and novel agents like cefiderocol and CZA‐ATM are emerging alternatives but require further validation.
Chowdhury J +4 more
europepmc +2 more sources
In-vitro evaluation of different antimicrobial combinations with and without colistin against carbapenem-resistant acinetobacter baumannii [PDF]
, 2019 Carbapenem-resistant Acinetobacter baumannii (CR-Ab) infections are associated with high morbidity and mortality. The aim of the study was to evaluate the in-vitro activity of different antimicrobial combinations (with and without colistin, COL) against ...
De Angelis, Massimiliano +6 more
core +1 more source